Characterization of proteinuria and tubular protein uptake in a new model of oral L-lysine administration in rats.
Intravenous infusion of basic amino acids is used experimentally and pharmacologically to prevent renal proximal tubular uptake of filtered proteins. Intravenously injected L-lysine is rapidly cleared from plasma and the effect on tubular protein reabsorption is transient. To obtain a more sustained effect, we developed a model of oral L-lysine administration and characterized this model by analyzing urinary protein excretion and proximal tubule uptake of filtered proteins. Rats placed in metabolic cages were treated with 20 mmol/kg/6 h of L-lysine, glycine, or water. Urines were analyzed for proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblotting, and radioimmunoassay. Proximal tubule uptake of proteins and expression of apical membrane receptors were investigated by immunocytochemistry. In vitro uptake and receptor expression were studied using a yolk sac cell line. L-lysine administration produced increased urinary excretion of a large number of proteins while the effect on tubular accumulation of selected proteins was variable. L-lysine treatment induced changes in the localization of two receptors responsible for tubular endocytosis of filtered proteins. In conclusion, oral L-lysine treatment induced proteinuria, in particular albuminuria, as efficiently as previous reports on intravenous infusion. The effect on tubular protein accumulation was variable suggesting differential effects on tubular reabsorption and degradation of filtered proteins. Changes in tubular protein handling were accompanied by changes in the localization of the endocytic receptors, megalin, and cubilin. In vitro experiments supported the in vivo observations. The findings suggest that L-lysine may affect receptor trafficking in addition to possible effects on the direct binding of ligands to the receptors.
Thelle
K
K
Department of Cell Biology, Institute of Anatomy, University of Aarhus, Aarhus, Denmark. kat@ana.au.dk
Christensen
E I
EI
Vorum
H
H
Ørskov
H
H
Birn
H
H
D000284:Administration, Oral; D000818:Animals; D045744:Cell Line, Tumor; D015180:Electrophoresis, Gel, Two-Dimensional; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005455:Fluorescent Antibody Technique; D006651:Histocytochemistry; D015151:Immunoblotting; D007150:Immunohistochemistry; D007457:Iodine Radioisotopes; D007687:Kidney Tubules, Proximal / Q000378:metabolism* / Q000648:ultrastructure; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D026561:Low Density Lipoprotein Receptor-Related Protein-2 / Q000378:metabolism; D008239:Lysine / Q000008:administration & dosage*; D018613:Microscopy, Confocal; D008954:Models, Biological; D011507:Proteinuria / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D011956:Receptors, Cell Surface / Q000378:metabolism / Q000502:physiology; D012710:Serum Albumin, Bovine / Q000493:pharmacokinetics; D016622:Silver Staining
D007457:Iodine Radioisotopes; D026561:Low Density Lipoprotein Receptor-Related Protein-2; D011956:Receptors, Cell Surface; C029486:intrinsic factor-cobalamin receptor; D012710:Serum Albumin, Bovine; D007770:L-Lactate Dehydrogenase; D008239:Lysine